These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 28135089)

  • 1. Emergence of Small-Molecule Non-RGD-Mimetic Inhibitors for RGD Integrins.
    Miller LM; Pritchard JM; Macdonald SJF; Jamieson C; Watson AJB
    J Med Chem; 2017 Apr; 60(8):3241-3251. PubMed ID: 28135089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterisation of a novel, high affinity and selective αvβ6 integrin RGD-mimetic radioligand.
    Hall ER; Bibby LI; Slack RJ
    Biochem Pharmacol; 2016 Oct; 117():88-96. PubMed ID: 27501918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-activity relationships of beta-amino acid-containing integrin antagonists.
    Scarborough RM
    Curr Med Chem; 1999 Oct; 6(10):971-81. PubMed ID: 10519908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Arginine-Glycine-Aspartate-Binding Integrins as Therapeutic and Diagnostic Targets.
    Sun CC; Qu XJ; Gao ZH
    Am J Ther; 2016; 23(1):e198-207. PubMed ID: 24621642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular mimicry of integrin ligation: therapeutic potential of arginine-glycine-aspartic acid (RGD) peptides.
    Goligorsky MS; Kessler H; Romanov VI
    Nephrol Dial Transplant; 1998 Feb; 13(2):254-63. PubMed ID: 9509431
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacological characterisation of GSK3335103, an oral αvβ6 integrin small molecule RGD-mimetic inhibitor for the treatment of fibrotic disease.
    Wilkinson AL; John AE; Barrett JW; Gower E; Morrison VS; Man Y; Pun KT; Roper JA; Luckett JC; Borthwick LA; Barksby BS; Burgoyne RA; Barnes R; Fisher AJ; Procopiou PA; Hatley RJD; Barrett TN; Marshall RP; Macdonald SJF; Jenkins RG; Slack RJ
    Eur J Pharmacol; 2021 Dec; 913():174618. PubMed ID: 34762934
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disintegrins: RGD-containing proteins which inhibit cell/matrix interactions (adhesion) and cell/cell interactions (aggregation) via the integrin receptors.
    Williams JA
    Pathol Biol (Paris); 1992 Oct; 40(8):813-21. PubMed ID: 1484742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrins in drug targeting-RGD templates in toxins.
    Lu X; Lu D; Scully MF; Kakkar VV
    Curr Pharm Des; 2006; 12(22):2749-69. PubMed ID: 16918409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovirus inhibition by peptidomimetic integrin antagonists.
    Hippenmeyer PJ; Ruminski PG; Rico JG; Lu HS; Griggs DW
    Antiviral Res; 2002 Jul; 55(1):169-78. PubMed ID: 12076761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic inhibition of RGD-binding integrins ameliorates fibrosis and improves function following kidney injury.
    Basta J; Robbins L; Stout L; Prinsen MJ; Griggs DW; Rauchman M
    Physiol Rep; 2020 Apr; 8(7):e14329. PubMed ID: 32281744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The first synthetic receptor for the RGD sequence.
    Rensing S; Schrader T
    Org Lett; 2002 Jun; 4(13):2161-4. PubMed ID: 12074657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists.
    Sheldrake HM; Patterson LH
    J Med Chem; 2014 Aug; 57(15):6301-15. PubMed ID: 24568695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of integrin antagonists containing trans- and cis-2,5-disubstituted THF rings.
    Osterkamp F; Ziemer B; Koert U; Wiesner M; Raddatz P; Goodman SL
    Chemistry; 2000 Feb; 6(4):666-83. PubMed ID: 10807178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural basis for ligand recognition by RGD (Arg-Gly-Asp)-dependent integrins.
    Takagi J
    Biochem Soc Trans; 2004 Jun; 32(Pt3):403-6. PubMed ID: 15157147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disruption of integrin-fibronectin complexes by allosteric but not ligand-mimetic inhibitors.
    Mould AP; Craig SE; Byron SK; Humphries MJ; Jowitt TA
    Biochem J; 2014 Dec; 464(3):301-13. PubMed ID: 25333419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural requirements of MLD-containing disintegrins for functional interaction with alpha 4 beta 1 and alpha 9 beta1 integrins.
    Bazan-Socha S; Kisiel DG; Young B; Theakston RD; Calvete JJ; Sheppard D; Marcinkiewicz C
    Biochemistry; 2004 Feb; 43(6):1639-47. PubMed ID: 14769041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative specificity of platelet alpha(IIb)beta(3) integrin antagonists.
    Thibault G; Tardif P; Lapalme G
    J Pharmacol Exp Ther; 2001 Mar; 296(3):690-6. PubMed ID: 11181894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging therapeutic opportunities for integrin inhibitors.
    Slack RJ; Macdonald SJF; Roper JA; Jenkins RG; Hatley RJD
    Nat Rev Drug Discov; 2022 Jan; 21(1):60-78. PubMed ID: 34535788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban.
    Mousa SA; Bozarth JM; Naik UP; Slee A
    Br J Pharmacol; 2001 Jun; 133(3):331-6. PubMed ID: 11375248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relative orientation of the Arg and Asp side chains defined by a pseudodihedral angle as a key criterion for evaluating the structure-activity relationship of RGD peptides.
    Kostidis S; Stavrakoudis A; Biris N; Tsoukatos D; Sakarellos C; Tsikaris V
    J Pept Sci; 2004 Aug; 10(8):494-509. PubMed ID: 15347137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.